IPCA Laboratories Limited — Investor Meet, 04-06-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Ipca Laboratories reported FY26 consolidated revenue growth of 8% to INR 9,646 Cr, with EBITDA margins improving to 20.72%. Domestic formulations grew 10% to INR 3,817 Cr, while API business saw 10% growth. Export formulations rose 9%. Management expects 12-13% consolidated growth and 22-22.3% EBITDA margins for FY27, driven by product mix and strategic launches. Rising raw material and freight costs are a concern, but the company plans to offset these via price hikes and efficiency. Unichem's margins are projected to improve to 12-13% in FY27. Management maintains a confident outlook on future performance.